Best Oncology Companies in Colorado, United States
The 45 best Oncology companies in Colorado, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Biodesix.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Colorado
| # | Company | Disclosed funding | Last round | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|
| 1 | Biodesix Developer of diagnostics assays for the detection of cancer | $200M | 45 mo ago | 217 217 → 360 (+66%) | — | 225 patents Molecular diagnostic assays and AI-driven biomarker analysis for cancer and infectious diseases | — |
| 2 | OnKure Therapeutics Developer of epigenetic therapies for the treatment of cancer. | $195M | 22 mo ago | 35 | Tony Piscopio Co-founder | — | — |
| 3 | Rezolute Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI) | $191M | 70 mo ago | 51 51 → 73 (+43%) | Nevan Elam Co-Founder & CEO | 89 patents Therapeutic antibodies targeting insulin receptor and plasma kallikrein inhibitors for oncology/metabolic diseases | — |
| 4 | ArcherDX Developer of molecular cancer diagnostic products | $153M | 80 mo ago | 429 | John Iafrate Co-Founder | 107 patents Patents concentrated in chemistry & materials | — |
| 5 | Enliven Therapeutics Developer of drugs for solid tumours and blood cancers | $140M | 29 mo ago | 27 | Anish Patel Co-Founder | — | — |
| 6 | GlobeImmune Developing Tarmogen (vaccine) product candidates to treat cancer and infectious diseases. | $132M | 113 mo ago | 1 | — | 423 patents Yeast‑based cancer immunotherapies delivering tumor antigens such as brachyury. | — |
| 7 | Foresight Diagnostics Developer of minimally-invasive liquid biopsy test for the detection of cancer | $104M | 24 mo ago | 35 | Ash Alizadeh Co-Founder | — | — |
| 8 | Integrated Diagnostics Blood-based diagnostics for oncology. | $83M | 116 mo ago | 17 | — | 67 patents Molecular diagnostic assays for lung cancer and neurodegenerative disease biomarkers | — |
| 9 | TriSalus Life Sciences Developer of drug delivery devices to treat cancers | $72M | 15 mo ago | 100 100 → 128 (+28%) | Mary Szela CEO and President | 113 patents Targeted turbulent-flow catheter drug delivery and TLR9‑based immunotherapy for cancer | — |
| 10 | Nexo Therapeutics Developer of therapeutics for cancer treatment | $60M | 45 mo ago | 6 | Michael Kim Co-Founder | — | — |
| 11 | MiRagen Developer of microRNA-based therapeutic solutions for treating multiple diseases | $44M | 69 mo ago | 92 | Sanjoy Mahanty Co-Founder | — | — |
| 12 | Precision Biopsy Developed system for prostate biopsies & diagnosis of prostate cancer | $41M | 118 mo ago | 13 | — | — | — |
| 13 | Rx Kinetix Developer of therapeutics for cancer treatment | $35M | 253 mo ago | — | Rajiv Desilva CEO | — | — |
| 14 | CellPoint Developer of intra-nuclear molecular imaging and therapeutics for multiple diseases | $30M | 62 mo ago | 185 | — | 4 patents Targeted peptide-drug conjugates for tissue-specific disease imaging | — |
| 15 | Taiga Biotech Cellular therapies for hematological diseases. | $27M | 72 mo ago | 2 | — | — | — |
| 16 | Arpeggio Provider of drug discovery platform for the treatment of cancer 24Funding top 27%Moat top 31%Talent top 38%Global bottom 37% All 6 signals ▾Fundingtop 27% Moattop 31% Talenttop 38% Globalbottom 37% Marketbottom 25% Newsbottom 22% Funding: Raised $25.4M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 24/100 | $25M | 9 mo ago | 8 | Laura Norris Co-Founder | — | — |
| 17 | Clovis Oncology Developer of immunotherapy drugs for the treatment of cancer | $20M | 69 mo ago | 280 | — | 49 patents Combination cancer immunotherapy with anti‑angiogenic agents and high‑dose PARP inhibitor formulations. | — |
| 18 | OncoVerity Developer of therapeutics for the treatment of cancer | $14M | 21 mo ago | — | Max Colao CEO | — | — |
| 19 | SiVEC Biotechnologies Revolutionizing therapeutics with targeted live biotherapeutic delivery platform for advanced solutions | $7M | 11 mo ago | 5 | Lyndsey Linke Co-Founder & CEO | 37 patents Bacterial vector platforms for intracellular delivery of antibodies, mRNA, and therapeutic proteins | — |
| 20 | Rock Immune Developer of immunotoxins for cancer therapy | $7M | 17 mo ago | — | Zhirui Wang Founder | — | — |
| 21 | Photonpharma Provider of antigen presentation technology | $6M | 24 mo ago | 3 | Amanda Guth Co-Founder & CSO | — | — |
| 22 | Orbit Genomics Developer of cancer diagnostics and companion diagnostics for drugs in development | $4M | 16 mo ago | 6 | Dede Willis Co-Founder & CEO | 15 patents Microsatellite genotyping and sample classification tools for genomic analysis | — |
| 23 | Fischer Medical Technologies Innovating diagnostic imaging for early and accurate breast cancer detection | $4M | 17 mo ago | 5 | Morgan Nields President & CEO | — | — |
| 24 | BioMimetix Developer of metalloporphyrin based agents to treat inflammatory skin disease | $3M | 83 mo ago | 6 | James Crapo CEO | 43 patents Radioprotective and ischemia‑reperfusion injury drugs using metalloporphyrin and peptide formulations | — |
| 25 | Triopsy Developer of medical device for cancer diagnosis | $2M | 31 mo ago | 5 | David Bostwick CEO | — | — |
| 26 | Cetya Therapeutics Early-stage biotech developing drug candidates using a proprietary HDACi platform based on Largazole analogs | $2M | 107 mo ago | 2 | — | — | — |
| 27 | Eleven P15 Developer of genetically-targeted therapeutic for pulmonary fibrosis | $2M | 81 mo ago | — | David Schwartz Founder | 5 patents Early detection of pulmonary fibrosis via circulating biomarker assays | — |
| 28 | AkesoGenX Nano-diagnostic and nano-therapeutic medical products for the treatment of cancer | $2M | 151 mo ago | — | Robert Zavala Founder | — | — |
| 29 | Source MDx Molecular diagnostic solutions for early detection of cancer | $2M | 198 mo ago | — | — | 19 patents Cross-species gene expression panels for diagnosing and monitoring autoimmune diseases | — |
Top 12 Oncology companies in Colorado
#1
Series B · Boulder, Colorado · founded 2017 · 8 employees$25.4Mraised▾
Provider of drug discovery platform for the treatment of cancer. The company uses DNA sequencing and CRISPR-based screening technology to identify therapeutic targets and biomarkers to treat cancer. The company is developing drug candidates for Sarcomas, Lung Adenocarcinoma, and autoimmune diseases.
- Nov 2025Series B$20M
- Mar 2025Series A$4M
- Aug 2022Series A$20.2M
- Jan 2020Seed$3.2M
#2
Public · Westminster, Colorado · founded 2009 · 100 employees$72.3Mraised▾
TriSalus Life Sciences is involved in developing drug delivery devices to treat cancers. They have developed a technology platform, Pressure-Enabled Drug Delivery (PEDD), which is designed to improve the distribution and penetration of therapy in solid tumors.
- Apr 2025Post IPO$22M
- Dec 2024Post IPO$1000K
- Oct 2022Post IPO$15.3M
- Sep 2021Post IPO$23.5M
#3
Public · Longmont, Colorado · founded 2011 · 35 employees$195.2Mraised▾
Developer of epigenetic therapies for the treatment of cancer. It's lead drug ONK179, an HDAC 6 inhibitor which is being developed for the treatment of hematological and solid tumor cancers and ONK102 has reduced the growth rate of tumours when dosed by itself or in combination with other targeted therapies.
- Oct 2024Series C$65M
- Mar 2023Series C$54M
- Mar 2021Series B$56.6M
- Sep 2020Series A$1.5M
#4
Series A · Fort Collins, Colorado · founded 2016 · 5 employees$7.2Mraised▾
Revolutionizing therapeutics with targeted live biotherapeutic delivery platform for advanced solutions. They are pioneering the next generation of therapeutics through their innovative BactPac delivery platform, enabling unparalleled therapeutic precision. This platform uses specialized bacteria engineered to safely deliver therapeutic payloads like mRNA, siRNA, proteins, and CRISPR/Cas to targeted tissues, reaching a wide range of tissues. They focus on providing industry partners with a safe and targeted delivery platform, ensuring nucleic acid and gene therapies excel in clinical trials. Their mission is to advance biologics and out-license the platform to pharma companies needing a safe, tissue-targeted delivery method. They are dedicated to transforming health by overcoming the limitations of traditional drug delivery, offering faster production, scalability, and reduced costs. Their team of scientists, innovators, and thinkers are committed to advancing therapeutic solutions through rigorous science and a shared vision for the future of medicine.
- Aug 2025Series A$3.3M
- Sep 2021Grant (prize money)$286.1K
- May 2020Grant (prize money)$250K
- Aug 2018Grant (prize money)$3.3M
#5
Acquired · Aurora, Colorado · founded 2020 · 35 employees$104.2Mraised▾
Developer of minimally-invasive liquid biopsy test for the detection of cancer. The company uses PhasED-Seq technology to develop liquid biopsy testing platform enabling detection of ctDNA levels in patients with solid tumors and hematologic malignancies.
- Jul 2024Series B$33M
- Apr 2023Series B$58.8M
- Jun 2021Series A$12.5M
#6
Seed · Wheat Ridge, Colorado · founded 2006 · 5 employees$3.8Mraised▾
Innovating diagnostic imaging for early and accurate breast cancer detection. The company focuses on developing solutions for the early and accurate detection and diagnosis of breast cancer, enabling personalized care and improved patient outcomes. With roots tracing back over a century in diagnostic imaging, the company continues a legacy of quality and innovation. The company is developing an array of solutions for early and accurate detection and diagnosis of breast cancer. The company is developing products like digital mammography and tomosynthesis with features like no compression and less radiation dose. The company is committed to advancing breast cancer diagnostics through groundbreaking inventions and a multifaceted approach to detection, diagnosis, and treatment.
- Mar 2025Grant (prize money)$2M
- Mar 2022Grant (prize money)$2M
- Apr 2019Grant (prize money)$355K
- Jun 2018Grant (prize money)$301.6K
#7
Seed · Boulder, Colorado · founded 2016 · 6 employees$4Mraised▾
Developer of cancer diagnostics and companion diagnostics for drugs in development. The company has developed technologies to accurately measure microsatellite variations and associate those variations with diseases, creating new diagnostic tools to evaluate the risk of certain cancers and for actionable clinical decision support. The company is currently developing a liquid biopsy test for the early detection of lung cancer and is also in the process of developing companion diagnostics.
- Apr 2025Grant (prize money)$2M
- Sep 2024Grant (prize money)$999.6K
- Jul 2024Seed$780K
- May 2021Grant (prize money)$250K
#8
Funding Raised · Aurora, Colorado · founded 2020$6.7Mraised▾
Developer of immunotoxins for cancer therapy. The company focused on the development and commercialization of diphtheria toxin-based recombinant immunotoxins for treatment of cancer & autoimmune diseases. The company's product include CCR4-IL2 bispecific immunotoxin for Cutaneous T-cell Lymphoma.
- Mar 2025Grant (prize money)$2.4M
- Aug 2022Grant (prize money)$4.3M
#9
Series A · Aurora, Colorado · founded 2022$14Mraised▾
Developer of therapeutics for the treatment of cancer. The company is pioneering the use of clinical and single cell multiomics database to advance the development of cusatuzumab, a novel anti-CD70 antibody, for the treatment of acute myeloid leukemia (AML) and other cancers.
- Nov 2024Series A$14M
#10
Public · Boulder, Colorado · founded 2019 · 27 employees$140Mraised▾
Developer of drugs for solid tumors and blood cancers. It offers precision oncology therapeutics which include ELVN-001, a small molecule kinase inhibitor that target the BCR-ABL gene fusion, andELVN-002 a HER2 inhibitor with activity against various HER2 mutations for non-small cell lung cancer and solid tumors.
- Mar 2024Post IPO$90M
- Feb 2023Post IPO$165M
- Dec 2020Post IPO$85M
- 2020Post IPO—
#11
Public · Boulder, Colorado · founded 2005 · 217 employees$200.2Mraised▾
Developer of diagnostics assays for the detection of cancer. The company offers invitro-diagnostic tests including Nodify Lung testing consisting of two blood-based proteomic tests, to identify the risk of malignancy of a lung nodule, and GeneStrat NGS a broad tumor mutation testing.
- Nov 2022Post IPO$40.3M
- Apr 2022Post IPO$11.7M
- Mar 2022Post IPO—
- Dec 2019Series F$3M
#12
Seed · Fort Collins, Colorado · founded 2019 · 3 employees$5.8Mraised▾
Photon Pharma provides antigen presentation technology. It provides personalized same-day immunotherapy for solid and liquid tumors. The product Innocell live, replication-inactivated tumor cells, same day autologous inoculation. It completely inactivates the treated tumor cells and triggers an immune response.
- Aug 2024Seed$2.5M
- May 2024Seed$350K
- Aug 2023Seed$2.9M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
How research on Oncology in Colorado is moving
A read on the academic research around Oncology in Colorado — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 138 papers.
- University of Colorado Anschutz Medical Campus93
- University of Colorado Denver46
- University of Colorado Cancer Center21
- Colorado State University15
- Children\'s Hospital Colorado10
- Tumor microenvironment1→26
- Cancer research3→16
- Immune system1→12
- Immunotherapy1→12
- Metastasis1→3
- Tumor microenvironment2→37
- Immune system3→28
- Cancer research4→25
- Immunotherapy2→10
- Cancer3→10
- Immunotherapy1→8
- Tumor microenvironment1→4
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.